EVERIMPACT
14.12.2022 16:50:36 CET | Business Wire | Press release
Everimpact, a Climate tech start-up founded by former UN execs and headquartered at Station F (Paris), closes a €1.711M seed funding round backed by leading VCs, corporate ventures and institutions to better measure carbon emissions and allow cities and high emitters to access climate finance to fund impactful climate projects.
The round, led by Motion ventures, includes international organizations, transport companies and impact investors; EU Commission (Climate-Kic and EIT Urban Mobility), Asian Development Bank (ADB Ventures), Transport Companies' VCs and CVCs (Wilhelmsen, Transport Capital, IMC Ventures, MOL PLUS, Blue Star Group) and Impact investors (Rainmaking Impact).
While greenhouse gas emissions (GHG) have been increasingly under scrutiny in the past years, they are mainly self-reported by emitters, based on estimates and updated once a year at best.
Everimpact’s carbon Monitoring, Reporting, and Verification (MRV) platform allows cities and organisations to measure GHG emissions more accurately and in real time, thanks to satellite, ground sensors, and AI data.
Everimpact also certifies carbon emissions and sequestration data to allow cities and industries to better identify reduction opportunities and access carbon finance to fund projects with a demonstrable climate impact.
The start-up is already working with the cities of Dijon (France) with EDF and British cities - in partnership with BT - to monitor and monetise their emissions. Several other cities from the Net Zero City initiative have expressed interest since attracting funding into transport, waste and building decarbonisation is key to successfully implement City Climate contracts. In Japan, Everimpact is partnering with Hitachi Systems to monitor carbon sequestration in municipal forests.
The backing of Everimpact by maritime and supply chain leaders also involves an engineering collaboration aiming at installing its solution onboard vessels to accurately measure their emissions and get access to carbon markets to finance decarbonisation.
This will help the shipping industry accelerate its decarbonisation while complying with significant changes in its environmental regulation such as the Carbon Intensity Indicator rating kicking in 2023 and the inclusion of maritime emissions in the EU Emissions Trading Systems in the next two years.
The funding will be used to expand carbon monitoring and monetisation capabilities in cities at a global level and expand the shipping measurement solution currently trialed on a Mitsubishi Corporation Group vessel and available through an Early Adopter Program.
Mathieu Carlier, CEO and Founder at Everimpact
“Cities and high emitters have a crucial role to play to accelerate the transition to a low carbon world. Thanks to Everimpact's innovative carbon tracking system, they are now able to move away from estimates to monitor their carbon footprint in real time, identify the best opportunities to cut emissions, and access new funding for their decarbonisation projects. We’re excited to partner with leading global organisations and investors to accelerate our development.”
Nicklas Viby Fursund, General Partner of Motion Ventures said: “Bringing together those from the public and private sector with the most influence on maritime and global supply chains is unprecedented. The pairing of the engineering collaboration and strategic capital is not just a milestone for Everimpact but a proof point for a consortium approach to innovation.”
About Everimpact
Everimpact helps cities and businesses accurately measure their greenhouse gas emissions, identify opportunities to reduce emissions, and finance required investments through the carbon markets.
While most cities and businesses report GHG emissions based on estimates, Everimpact IoT software combines satellite, ground sensors, and AI data to precisely measure emissions in real-time.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005661/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
